SAB Biotherapeutics (SABS) Accounts Payables (2020 - 2026)

SAB Biotherapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• Quarterly Accounts Payables rose 40.65% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 40.65% YoY) and the FY2025 annual result came in at $3.1 million, up 85.62% from the prior year.
• Accounts Payables was $3.5 million for Q1 2026 at SAB Biotherapeutics, up from $3.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.5 million in Q3 2022 and bottomed at $945927.0 in Q4 2023.
• A 5-year average of $2.6 million and a median of $2.5 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables plunged 80.25% — and 2025, when it jumped 127.83%.
• SAB Biotherapeutics' Accounts Payables stood at $3.7 million in 2022, then sank by 74.29% to $945927.0 in 2023, then soared by 79.16% to $1.7 million in 2024, then soared by 85.62% to $3.1 million in 2025, then climbed by 12.69% to $3.5 million in 2026.
• Business Quant data shows SABS's Accounts Payables at $3.5 million in Q1 2026, $3.1 million in Q4 2025, and $3.0 million in Q3 2025.